Share Page
Post on LinkedIn
Copy URL to Clipboard
Copied!

What can be expected from the development of preventive vaccines for non virally-induced cancers?

The introduction of prophylactic vaccines for virally-induced cancers (primarily HBV and HPV) has achieved a tremendous impact on disease related deaths. This has, in time, raised interest in developing vaccines to intercept pre-cancerous cells based on their expression of aberrant self-antigens (e.g. hypoglycosilated MUC1 in colon, lung and breast carcinomas). As of 2024, a number of phase I clinical studies have been ongoing in the USA, for both primary prevention and early cancer interception in genetically susceptible individuals (e.g. Kras and BRCA1/2 mutation carriers, Lynch syndrome). For more details, please check 
Stanton et al. Advances and challenges in cancer  immunoprevention and  immune interception.  J Immunother Cancer 2024
McKeague et al. Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions. Antibodies (Basel), 2024 


Post an Answer

Sign In to Answer
2 Answers
Accepted, Highest Scores first Newest first
0
Gavs1540
The shift toward "immune interception" using prophylactic vaccines is completely changing how we approach non-viral cancers. Instead of waiting for late-stage disease, the focus is now on stopping cancer before it truly begins. Looking at the Phase I trials currently being run since 2024, a few major clinical shifts really stand out.

First, these vaccines aren't really meant for the general public just yet. They are going to be game-changers for high-risk groups, specifically patients with known genetic predispositions like Lynch syndrome or BRCA1/2 mutations, or those with known precancerous lesions like colon adenomas. If we can train the immune system early on, we might be able to spare these patients from having to undergo aggressive prophylactic surgeries or constant, intensive screening protocols.

The biological mechanism here is fascinating because, unlike the HPV or HBV vaccines that target foreign viruses, these new vaccines have to target our own abnormally expressed proteins. We are looking at targets like hypoglycosylated MUC1 in breast, colon, and lung carcinomas, or KRAS mutations. The goal isn't just to trigger a quick antibody response. We want to build a durable T-cell response, involving both CD4+ and CD8+ cells, so the body essentially sets up a permanent, internal surveillance system to catch and eliminate precancerous cells over a person's lifetime.

We are also likely going to see these vaccines paired with immune modulators. Precancerous cells are notoriously good at evading immune surveillance, so combining vaccines with IL-15 superagonists or immune checkpoint inhibitors will be crucial to getting a strong enough therapeutic effect.

Of course, there are still some massive hurdles to clear before this becomes standard clinical practice. The biggest issue is safety. Breaking the body's natural immune tolerance to its own proteins is risky because you can easily trigger autoimmune diseases if you aren't incredibly precise. On top of that, running clinical trials for cancer prevention takes a notoriously long time. We really need better screening criteria to define the exact "window of opportunity" for vaccination, along with reliable biomarkers so we can prove the vaccines actually work without having to wait decades for trial results.

Ultimately, the move toward non-viral cancer vaccines represents a massive leap for preventive medicine, pushing us to intercept the disease at the cellular level rather than just treating it after the fact.

0
Qin

Drawing on the successful experience of HPV and HBV vaccines, the current research focus is shifting towards intercepting precancerous lesion cells. These vaccines are no longer targeted at foreign viruses, but target the abnormally expressed autoantigens (such as low glycosylated MUC1 in colon cancer, lung cancer, and breast cancer). In the future, it is expected to provide a "immune monitoring" method for high-risk populations to eliminate cancer cells before they form.

With the advancement of multiple Phase I clinical trials in the United States in 2024, preventive vaccines are gradually being combined with genetic screening. For individuals carrying genetic susceptibility genes such as Kras mutations, BRCA1/2 mutations, or Lynch syndrome, vaccines have the potential to become a customized early intervention to delay or even block their cancer progression.

As shown in McKeague et al.'s research, antibodies induced by vaccines not only have specificity, but also multiple effector functions (such as ADCC, complement activation, etc.). In the future, we can expect vaccines to not only induce humoral immunity, but also mobilize T cell immunity, form more lasting immune memory, and achieve long-term monitoring of precancerous lesions.

Although the prospects are promising, it is still necessary to overcome the issues of immune tolerance to self antigens, vaccine safety (to avoid inducing autoimmune diseases), and screening criteria for biomarkers. In addition, how to define the "pre cancerous state" and determine the optimal vaccination timing is also a key challenge in clinical translation.
Type
Public
Status
Answered
Bounty
1 Ping Credit
Created
03/02/2026
Answer Count
2
Vote Count
0
Creator
Alessandra Rossi
Tags
Academia Immunology Oncology